Systematic review of current studies of the problem of serological non-responsiveness after treatement of syphilitic infection

Drozhdina M.B.

Kirov State Medical University of the Ministry of health of the Russian Federation

The article presents modern data on the epidemiology, predisposing factors, comorbidity of slow seronegativity and seroresistance after treatment of syphilis. Described evidence base of the relationship of seroresistance and the main complex of HLA histocompatibility. The risk of seroresistance in the owners of the antigen B18 is 2 times higher compared to persons who do not have this antigen in their phenotype. Identified histocompatibility antigen B5 in patients with syphilis requires the appointment of penicillin drugs due to lower risk of seroresistance in this case. On the contrary, for the owners of the phenotype B7-B18, the appointment of penicillin is not advisable, since the risk of seroresistance is 4.7 times higher. Male carriers of the antigen DRB1*10 are 4.1 times more likely to demonstrate seroresistance after treatment of syphilis compared with persons who do not have the said antigen in their phenotype. Allele DRB1*04 has preventive properties in relation to the formation of seroresistance after syphilis in male patients.